Olanzapine use in adolescent anorexia nervosa

  • K. Dennis
  • D. Le Grange
  • J. Bremer
Case Report


Several case reports and open label trials describe olanzapine in the treatment of anorexia nervosa (AN). We report 5 adolescents with AN who received olanzapine in addition to psychotherapy for their eating disorder. Body mass index (BMI) of each case increased while on olanzapine. At doses of 5 mg per day and above, patients reported decreased anxiety around eating, improved sleep, and decreased rumination about food and body concerns. Morning sedation was the most commonly reported adverse effect. Olanzapine appeared to be useful in addition to psychotherapy for these adolescents. This report augments a limited literature on the treatment of this disorder, and an almost nonexistent literature specific to pharmacotherapy for adolescents with AN.

Key words

Olanzapine anorexia nervosa adolescents 


  1. 1.
    Walsh B.T., Kaplan A.S, Attia E., Carter J., Devlin M.J., Olmsted M., Pike K.M., Woodside B., Parides M.: Fluoxetine vs. Placebo to prevent relapse in anorexia nervosa: Primary outcome of drug on time to relapse in 93 weight restored subjects. Paper presented at the Eating Disorders Research Society, Toronto, September, 2005.Google Scholar
  2. 2.
    Vandereycken W.: Neuroleptics in the short-term treatment of anorexia nervosa: A double-blind placebo-controlled study with sulpiride. Br. J. Psychiatry, 144, 288–292, 1984.PubMedCrossRefGoogle Scholar
  3. 3.
    Halmi K., Eckert E., LaDu T., Cohen J.: Anorexia nervosa: Treatment efficacy of cyproheptadine and amitriptyline. Arch. Gen. Psychiatry, 43, 177–181, 1986.PubMedCrossRefGoogle Scholar
  4. 4.
    Kaye W.H., Weltzin T.E.: Serotonin activity in anorexia and bulimia nervosa: relationship to the modulation of feeding and mood. J. Clin. Psychiatry, 52, 41–48, 1991.PubMedGoogle Scholar
  5. 5.
    Frank G.K., Kaye W.H., Weltzin T.E., Perel J., Moss H., McConaha C, Pollice C: Altered response to meta-chlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration. Int. J. Eat. Disord., 30, 57–68, 2001.PubMedCrossRefGoogle Scholar
  6. 6.
    Boachie A., Goldfield G.S., Spettigue W.: Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa. Int. J. Eat. Disord., 33, 98–103, 2003.PubMedCrossRefGoogle Scholar
  7. 7.
    Attia E., Kaplan A.S., Schroeder L., Federici A., Staab R.: Atypical antipsychotic medication in anorexia nervosa. Paper presented at the Eating Disorders Research Society, Toronto, September, 2005.Google Scholar
  8. 8.
    Bosanac P., Norman T., Burrows G., Beumont P.: Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics? Aust. N. Z. J. Psychiatry, 39, 146–153, 2005.PubMedCrossRefGoogle Scholar
  9. 9.
    LaVia M.C., Gray N, Kaye W.H.: Case reports of olanzapine treatment of anorexia nervosa. Int. J. Eat. Disord., 27, 363–366, 2000.CrossRefGoogle Scholar
  10. 10.
    Mehler C., Wewetzer C., Schulze U., Warnke A., Theisen F., Dittmann R.W.: Olanzapine in children and adolescents with chronic anorexia nervosa. Eur. Child. Adolesc. Psychiatry, 10, 151–157, 2001.PubMedCrossRefGoogle Scholar
  11. 11.
    Powers P., Santana C., Bannon Y.: Olanzapine in the treatment of anorexia nervosa: an open label trial. Int. J. Eat. Disord., 32, 146–152, 2002.PubMedCrossRefGoogle Scholar
  12. 12.
    Mondraty N, Birmingham C.L., Touyz S., Sundakov V., Chapman L., Beaumont P.: Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Aust. Psychiatry, 13, 72–75, 2005.Google Scholar
  13. 13.
    Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J.: An inventory for measuring depression. Arch. Gen. Psychiatry, 4, 561–571, 1961.PubMedCrossRefGoogle Scholar

Copyright information

© Editrice Kurtis 2006

Authors and Affiliations

  1. 1.Eating Disorders Program, Department of PsychiatryThe University of ChicagoChicagoUSA

Personalised recommendations